<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01120925</url>
  </required_header>
  <id_info>
    <org_study_id>Royan-Liver-002</org_study_id>
    <nct_id>NCT01120925</nct_id>
  </id_info>
  <brief_title>Autologous Bone Marrow Derived Stem Cells in Decompensate Cirrhotic Patients</brief_title>
  <official_title>Comparison of Therapeutic Outcome of Twice Transplantation of CD133+ and MNC BM Derived Stem Cells in Cirrhotic Patients: Clinical Trial, Double Blind, Phase I/II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Tehran</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royan Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver cirrhosis (LC) is the final outcome for chronic liver diseases. The liver
      transplantation is the sole effective therapy available to these patients. However, limited
      number of donors, post surgical complications, immunological rejection, and financial
      consideration are it`s crucial problems. The plasticity of stem cells in bone marrow (BM) to
      differentiate into Hepatocyte cells was recently confirmed, and several clinical studies have
      applied BMC injection to induce regeneration of myocardium and blood vessels. In this study,
      the investigators will study safety and feasibility of twice transplantation of Autologous
      bone derived marrow mono nuclear (BM-MNC) and enriched CD133+ hematopoietic stem cell through
      the portal vein in patients with decompensate cirrhosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BM Aspiration will be done twice (3months interval) from the iliac crest according to
      standard procedures under general anesthesia and is collected (200ML) in plastic bags
      containing anti coagulant. After precipitation of red blood cells, mononuclear cells will be
      collected by centrifugation in Ficoll-Paque density gradient. For separation of CD133+ cells
      the CliniMACS instrument will be used. Cells are injected twice (3months interval) via portal
      vein under sonography monitoring. After cell therapy, patients are followed up every week for
      6 months, and laboratory data are analyzed for 6 months
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver function test</measure>
    <time_frame>6 months</time_frame>
    <description>Meld score, Child score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cirrhosis Mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>MNC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bone marrow derived MNC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD133</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD133 derived from Bone marrow</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline with 5% Human Serum Albumin</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MNC</intervention_name>
    <description>2-3 X 109 cells in 20ML suspension IPV in 4 min</description>
    <arm_group_label>MNC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD133</intervention_name>
    <description>5-15 X 106 cells in 20ML suspension IPV</description>
    <arm_group_label>CD133</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Injection of 20 ml Normal saline via IPV</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  16-65 Years cirrhotic patient

          -  Approved cirrhosis by elastografy ,biopsy, sonography

          -  Serum ALT 1/5 times more than normal

          -  MELD score 12 or Child score B or C

        Exclusion Criteria:

          -  Portal vein thrombosis

          -  Hepatic encephalopathy, score 3&amp;4

          -  ALT &amp; AST 3times more than normal

          -  Serum Cr more than 1/5mg/dL

          -  (Anti-HIV +) (Anti-HCV+) (HBS-Ag+)

          -  Hepatocel carcinoma

          -  Primary sclerosing cholangitis (PSC)

          -  Esophageal varices grade 4

          -  Addiction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamid Gourabi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reza Malekzadeh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gastroenterology and hepatic disease research center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hossein Baharvand, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Bagheri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gastroenterology and hepatic disease research center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Massoud Vosough, MD</last_name>
    <role>Study Director</role>
    <affiliation>Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nasser Aghdami, MD., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royan Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gastroenterology and hepatic disease research center</name>
      <address>
        <city>Tehran</city>
        <zip>14114</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://www.royaninstitute.org</url>
  </link>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2010</study_first_submitted>
  <study_first_submitted_qc>May 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2010</study_first_posted>
  <last_update_submitted>April 24, 2014</last_update_submitted>
  <last_update_submitted_qc>April 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cirrhotic</keyword>
  <keyword>Stem Cells</keyword>
  <keyword>Bone marrow stem cells</keyword>
  <keyword>Decompensate Cirrhotic Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

